Literature DB >> 17234747

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.

Ta-Chiang Liu1, David Kirn.   

Abstract

Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed.

Entities:  

Mesh：

Year:  2007        PMID： 17234747     DOI： 10.1158/0008-5472.CAN-06-2871

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  44 in total

1.  Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.

Authors:  Manish R Patel; Blake A Jacobson; Holly Belgum; Ahmad Raza; Ahad Sadiq; Jeremy Drees; Hengbing Wang; Joseph Jay-Dixon; Ryan Etchison; Mark J Federspiel; Stephen J Russell; Robert A Kratzke
Journal:  J Thorac Oncol       Date:  2014-08       Impact factor: 15.609

Review 2.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

3.  Activation of an antiviral response in normal but not transformed mouse cells: a new determinant of minute virus of mice oncotropism.

Authors:  Svitlana Grekova; Rainer Zawatzky; Rita Hörlein; Celina Cziepluch; Michal Mincberg; Claytus Davis; Jean Rommelaere; Laurent Daeffler
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

4.  Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice.

Authors:  Tiantian Zhang; Yogesh R Suryawanshi; Dennis H Kordish; Helene M Woyczesczyk; David Jeng; Karim Essani
Journal:  Virus Genes       Date:  2016-10-13       Impact factor: 2.332

5.  Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices.

Authors:  Michael-A van Geer; Koert F D Kuhlmann; Conny T Bakker; Fibo J W ten Kate; Ronald P J Oude Elferink; Piter J Bosma
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

6.  Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Authors:  Ta-Chiang Liu; Pedro Castelo-Branco; Samuel D Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

7.  Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

8.  Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68.

Authors:  Ivaylo Gentschev; Ulrike Donat; Elisabeth Hofmann; Stephanie Weibel; Marion Adelfinger; Viktoria Raab; Martin Heisig; Nanhai Chen; Yong A Yu; Jochen Stritzker; Aladar A Szalay
Journal:  J Biomed Biotechnol       Date:  2010-04-01

9.  Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

Authors:  E J Ilett; R J Prestwich; T Kottke; F Errington; J M Thompson; K J Harrington; H S Pandha; M Coffey; P J Selby; R G Vile; A A Melcher
Journal:  Gene Ther       Date:  2009-03-12       Impact factor: 5.250

Review 10.  Novel delivery methods to achieve immunomodulation.

Authors:  David J Gould; Yuti Chernajovsky
Journal:  Curr Opin Pharmacol       Date:  2007-07-03       Impact factor: 5.547
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.